Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture
Author(s) -
Henning Kempf,
Ruth Olmer,
Christina Kropp,
Michael Rückert,
Monica Jara-Avaca,
Diana Robles-Diaz,
Annika Franke,
David A. Elliott,
Daniel Wojciechowski,
Martin Fischer,
Angélica Roa Lara,
George Kensah,
Ina Gruh,
Axel Haverich,
Ulrich Martin,
Robert Zweigerdt
Publication year - 2014
Publication title -
stem cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.207
H-Index - 76
ISSN - 2213-6711
DOI - 10.1016/j.stemcr.2014.09.017
Subject(s) - induced pluripotent stem cell , bioreactor , biology , laboratory flask , microbiology and biotechnology , erlenmeyer flask , cell culture , suspension culture , stem cell , mesenchymal stem cell , regenerative medicine , cellular differentiation , embryonic stem cell , biochemistry , botany , chemistry , genetics , chromatography , gene
To harness the potential of human pluripotent stem cells (hPSCs), an abundant supply of their progenies is required. Here, hPSC expansion as matrix-independent aggregates in suspension culture was combined with cardiomyogenic differentiation using chemical Wnt pathway modulators. A multiwell screen was scaled up to stirred Erlenmeyer flasks and subsequently to tank bioreactors, applying controlled feeding strategies (batch and cyclic perfusion). Cardiomyogenesis was sensitive to the GSK3 inhibitor CHIR99021 concentration, whereas the aggregate size was no prevailing factor across culture platforms. However, in bioreactors, the pattern of aggregate formation in the expansion phase dominated subsequent differentiation. Global profiling revealed a culture-dependent expression of BMP agonists/antagonists, suggesting their decisive role in cell-fate determination. Furthermore, metallothionein was discovered as a potentially stress-related marker in hPSCs. In 100 ml bioreactors, the production of 40 million predominantly ventricular-like cardiomyocytes (up to 85% purity) was enabled that were directly applicable to bioartificial cardiac tissue formation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom